NASDAQ:ALLO

Allogene Therapeutics Stock Predictions

etoro logo Buy ALLO
*Your capital is at risk
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

ALLO Prediction Chart

ALLO Predictions History

Latest community submissions for ALLO.
Predictor Target Session Target Price Result Direction Accuracy Score
Feb 9, 2026 $1.75 +3.62% $1.69 X 96.38% 0
Feb 9, 2026 $1.73 +2.27% $1.69 X 97.74% 0
Feb 9, 2026 Bearish $1.69 X 0
Dec 4, 2025 $1.48 -2.52% $1.44 V 97.11% 1
Dec 4, 2025 $1.50 -1.58% $1.44 V 96.11% 1
Dec 4, 2025 $1.72 +13.16% $1.44 X 80.56% 0
Dec 4, 2025 Bullish $1.44 V 0
Sep 29, 2025 $1.22 -2.25% $1.27 X 96.21% 0
Sep 29, 2025 $1.23 -1.41% $1.27 X 97.04% 0
Sep 29, 2025 $1.28 +2.40% $1.27 V 99.21% 3
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for ALLO with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT ALLOGENE THERAPEUTICS INC.
Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE